Your browser doesn't support javascript.
loading
One-step solid-oil-water emulsion for sustained bioactive ranibizumab release.
Chua, Hui Yee; Lui, Yuan Siang; Bhuthalingam, Ramya; Agrawal, Rupesh; Wong, Tina; Preiser, Peter Rainer; Venkatraman, Subbu.
Afiliação
  • Chua HY; a Institute for Health Technologies, Interdisciplinary Graduate School , Nanyang Technological University , Singapore , Singapore.
  • Lui YS; b School of Materials Science and Engineering , Nanyang Technological University , Singapore , Singapore.
  • Bhuthalingam R; b School of Materials Science and Engineering , Nanyang Technological University , Singapore , Singapore.
  • Agrawal R; b School of Materials Science and Engineering , Nanyang Technological University , Singapore , Singapore.
  • Wong T; c Tan Tock Seng Hospital , Singapore , Singapore.
  • Preiser PR; d Singapore Eye Research Institute , Singapore , Singapore.
  • Venkatraman S; e School of Biological Sciences , Nanyang Technological University , Singapore , Singapore.
Expert Opin Drug Deliv ; 15(12): 1143-1156, 2018 12.
Article em En | MEDLINE | ID: mdl-30354700
ABSTRACT

BACKGROUND:

The advent of therapeutic proteins highlights the need for delivery systems that protect and extend the duration of its action. Ranibizumab-VEGF is one such drug used for treating wet AMD. This paper describes a facile method to sustain bioactive ranibizumab release from PLGA-based particles.

METHODS:

Two emulsion techniques were explored namely water-in-oil-in-water (WOW) and solid-in-oil-in-water (SOW) emulsion. The bioactivity of ranibizumab was evaluated by comparing its binding capability to VEGF, measured with ELISA to total protein measured by microBCA.

RESULTS:

During the emulsion process, contact of ranibizumab with the water-oil interface is the main destabilizing factor and this can be prevented with the use of amphiphilic PVA and solid-state protein in WOW and SOW emulsion respectively. In vitro release of the ranibizumab-loaded particles indicated that a 15-day release could be achieved with SOW particles while the WOW particles generally suffered from a burst release. Released ranibizumab was capable of inhibiting endothelial cell growth indicating its retention of bioactivity. The suppression of burst release from the SOW particles was attributed to the relatively smooth surface morphology of the SOW microparticles.

CONCLUSIONS:

The use of SOW encapsulation in modulating ranibizumab release while maintaining their bioactivity has been highlighted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Angiogênese / Ranibizumab / Copolímero de Ácido Poliláctico e Ácido Poliglicólico Idioma: En Revista: Expert Opin Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Singapura

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Angiogênese / Ranibizumab / Copolímero de Ácido Poliláctico e Ácido Poliglicólico Idioma: En Revista: Expert Opin Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Singapura